SCNI - Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston | Benzinga
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today that CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14).
Investors and potential business partners interested in meeting with Mr. Reichman and Mr. Germain are invited to contact Scinai investor relations at ir@scinai.com to request a meeting.
In addition, members of Scinai's senior leadership team will be attending the CPHI Barcelona conference in October. Events that Scinai plans to attend are listed on Scinai's new website at https://www.scinai.com/events.
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly ...